医学
肿块切除术
乳房切除术
乳腺癌
保乳手术
放射治疗
生活质量(医疗保健)
外科
淋巴水肿
术中放疗
癌症
内科学
护理部
作者
Hans‐Christian Kolberg,Helena Niesing,Jayant S Vaidya,Leyla Akpolat-Basci,Abdrhman Maguz,Oliver Hoffmann,Gyoergy Loevey,Miltiades Stephanou,Cornelia Kolberg‐Liedtke
出处
期刊:Anticancer Research
[Anticancer Research USA Inc.]
日期:2023-01-25
卷期号:43 (2): 733-739
被引量:1
标识
DOI:10.21873/anticanres.16212
摘要
Background/Aim: Mastectomy is the standard treatment of in-breast-recurrence of breast cancer after breast conserving surgery (BCS) and external beam radiation therapy (EBRT). In selected cases, it is possible to preserve the breast if targeted intraoperative radiotherapy (TARGIT-IORT) can be given during the second lumpectomy. This is a comparative analysis of overall survival and quality of life (QoL). Patients and Methods: Patients in our database with in-breast-recurrence and either mastectomy or BCS and TARGIT-IORT were included. Identified patients were offered participation in a prospective QoL-analysis using the BREAST-Q questionnaire. The cohorts were compared for confounding parameters, overall survival, and QoL. Results: Thirty-six patients treated for in-breast-recurrence were included, 21 had received a mastectomy and 16 patients had received BCS with TARGIT-IORT. Mean follow-up was 12.8 years since primary diagnosis and 4.2 years since recurrence. Both groups were balanced regarding prognostic parameters. Overall survival was numerically longer for BCS and TARGIT-IORT, but the numbers were too small for formal statistical analysis. No patient had further in-breast-recurrence. Psychosocial and sexual wellbeing did not differ between both groups. Physical wellbeing was significantly superior for those whose breast could be preserved (p-value=0.021). Patient-reported incidence and severity of lymphedema of the arm was significantly worse in the mastectomy group (p=0.007). Conclusion: Preserving the breast by use of TARGIT-IORT was safe with no re-recurrence and no detriment to overall survival in our analysis and led to a statistically significant improvement in physical wellbeing and incidence of lymphedema. These data should increase the confidence in offering breast preservation after in-breast-recurrence of breast cancer.
科研通智能强力驱动
Strongly Powered by AbleSci AI